Gensight Biologics (LTS:0RIM) Ending Cash Position : €2.46 Mil (As of Dec. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Gensight Biologics Ending Cash Position?

Gensight Biologics's Ending Cash Position for the quarter that ended in Dec. 2024 was €2.46 Mil.

Gensight Biologics's quarterly Ending Cash Position increased from Dec. 2023 (€2.13 Mil) to Jun. 2024 (€6.94 Mil) but then declined from Jun. 2024 (€6.94 Mil) to Dec. 2024 (€2.46 Mil).

Gensight Biologics's annual Ending Cash Position declined from Dec. 2022 (€10.61 Mil) to Dec. 2023 (€2.13 Mil) but then increased from Dec. 2023 (€2.13 Mil) to Dec. 2024 (€2.46 Mil).

Gensight Biologics Ending Cash Position Historical Data

The historical data trend for Gensight Biologics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gensight Biologics Ending Cash Position Chart

Gensight Biologics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Ending Cash Position

Get a 7-Day Free Trial

37.94

44.29

10.61

2.13

2.46

Gensight Biologics Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Ending Cash Position	Get a 7-Day Free Trial															10.61	1.02	2.13	6.94	2.46

Gensight Biologics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Gensight Biologics's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	2.135	+	0.329
	=	2.46

Gensight Biologics's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	6.941	+	-4.477
	=	2.46

Gensight Biologics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Gensight Biologics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Gensight Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gensight Biologics SA (LTS:0RIM) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

SIGHT:France

Address

74, rue du Faubourg Saint-Antoine, Paris, FRA, 75012

Website

https://www.gensight-biologics.com

Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence, and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group's focus is on ophthalmology where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.

Gensight Biologics Headlines

No Headlines